Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Oxford Nanopore Technologies PLC on Friday said it is participating in a cohort study led by the UK National Institute for Health and Care Research BioResource to explore human health and disease.
Oxford Nanopore is an Oxford, England-based company that develops and sells nanopore sequencing products.
The company said the the study, which will begin this year and expected to run until 2025, is set to involve the use of its platform to to sequence up to 22,000 samples. The samples will be used to further research into psychiatric common and rare disease.
The firm added that the resulting data will be made available to the scientific community, through a database hosted by the European Genome0phenome Archive.
Oxford Nanopore said the study will operate through a partnership between Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge.
Oxford Nanopore shares rose 0.7% to 214.00 pence each in London on Friday afternoon.
Copyright 2023 Alliance News Ltd. All Rights Reserved.